Skip to main content

Currently Enrolling Alzheimer’s Disease Studies

The success of finding new treatments depends on having enough volunteers like you to participate. To learn how you or a loved one can take part in any of these studies, call  913-588-0555 option 1 for more information, or you may complete the Apply for a Study form online.

Observational Studies

KU Alzheimer’s Disease Center Clinical Cohort
A National Institute of Health (NIH) grant funded study to develop and maintain a well characterized group of individual to support further research on memory and aging.

Type of Study: Observational (no treatment)
Who: Individuals with memory loss of any age and individuals without memory loss 65 and older
Procedures: Clinical memory assessment, pen and paper test, blood draw
Duration: up to 3 visits annually
Compensation: No

Relationship of Energetics and Cognitive Trajectory (REACT)
A study to characterize the relationship between metabolic hormone secretion, energy production, and memory.

Type of Study: Observational (no treatment)
Who: Clinical Cohort participants with and without memory loss, age 60 and older
Procedures: Mixed meal tolerance test, blood draws, MRI
Duration: 2 visits
Compensation: Yes

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
A public/private collaboration between academia and industry to study biomarkers and progression of Alzheimer’s disease.

Type of Study: Observational (no treatment)
Who: Individuals with normal cognition ages 65-90 and individuals with Mild Cognitive Impairment or mild Alzheimer’s disease ages 55-90
Procedures: Participants will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection
Duration: Up to five years, with annual visits
Compensation: Yes

Aging and Disease Mitochondria (ADMIT)
A study to test the relationship between energy production in cells, genetics, and fitness.

Type of Study: Observational (no treatment)
Who: Individuals with memory loss of any age and individuals without memory loss age 65 and older
Procedures: Blood draw, fitness test, muscle biopsy
Duration: 2 visits
Compensation: Yes

Prevention studies

Risk Reduction for Alzheimer’s disease (rrAD)
A study to test whether aggressive blood pressure and cholesterol lowering through medication and physical exercise can slow the cognitive decline and risk for developing dementia.

Type: FDA-approved medications, moderate intensity exercise or both
Who: Underactive individuals age 60+ with high blood pressure, and family history of dementia or concern about memory
Procedures: physical exam, pen and paper tests, questionnaires, blood draws, fitness tests, ECG, MRI, and vascular measures
Duration: 24 months of intervention
Compensation: Yes

Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE)
A study to explore the idea that physical activity may help maintain and improve brain health in older adults.

Type of Study: Treadmill walking or stretching and toning exercise at a local YMCA
Who: Individuals 65-80 who are not exercising regularly
Procedures: physical function tests, body composition measurements, MRI & PET scans, pen and paper tests, questionnaires, blood draws
Duration: 12 months of intervention, with about 4 visits a week
Compensation: Yes –YMCA membership paid

A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease (GENERATION)
Study of efficacy of CAD106 and CNP520 in comparison to respective placebo in participants at the risk for the onset of clinical symptoms of Alzheimer’s disease.

Type of Study: Investigational medicine (chance of placebo)
Who: Individuals with normal cognition, ages 60-75
Procedures: PET scans, MRI scans, blood draws, physical exams, memory testing, memory evaluations, questionnaires, other optional procedures
Duration: 5-8 years of study treatment with quarterly study visits, 25-37 visits total
Compensation: Yes

Treatment studies

Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic Alzheimer’s disease (TRAILBLAZER)
A study to assess the safety, tolerability and effectiveness of combination of LY3002813 (IV infusion) and LY3202626 (oral pill) in people with memory loss.

Type of Study Investigational medicine (chance of placebo)
Who: Individuals with memory loss of 6mo or more, age 60-85
Procedures: MRI’s, PET scans, Eye exam, Skin exam, pen and paper tests, questionnaires, blood draws, physical exams
Duration: 22+ visits over 27 months
Compensation: Yes

Therapeutic Effect of Exercise in Adults with Amnestic Mild Cognitive Impairment (EXERT)
A study to test whether physical exercise can slow the progression of early Alzheimer’s disease memory problems in older adults.

Type of Study: Low or moderate intensity exercise at local YMCA with personal trainer
Who: Underactive individuals with Mild Cognitive Impairment
Procedures: Physical exam, pen and paper tests, questionnaires, blood draws, fitness tests, ECG, MRI and optional lumbar puncture
Duration: 18 months of intervention with about 4 visits a week to the YMCA
Compensation: Yes -YMCA membership and personal trainer fees paid

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's disease (AWARE)
A study to evaluate a drug that may slow Alzheimer’s progression in those with early AD. The drug is designed to target tau tangles in the brain and will be delivered via IV.

Type of Study: Investigational medicine (chance of placebo)
Who: Individuals with Mild Cognitive Impairment or probable AD
Procedures: PET brain imaging, MRI brain imaging, 2-3 lumbar punctures, study drug infusion, ECG’s, blood draws, physical and neurological exams, memory and thinking tests, and questionnaires/interviews
Duration: ~2 ½ years, about 45 visits
Compensation: Yes

S-Equol in Alzheimer’s disease 2 (SEAD2)
A study to test if S-Equol, a compound that acts like estrogen in the body, can improve a particular energy metabolism deficit that is found in persons with Alzheimer’s disease (AD)

Type of Study: Investigational medicine (on placebo for half treatment duration and investigational medication the other half)
Who: Individuals with Alzheimer’s disease (APOE4 non-carriers)
Procedures: Genetic counseling, physical and neurological exams, blood draws, pen and paper thinking tests, vital signs
Duration: 4 months, 4 visits & 1 phone call
Compensation: Yes

The mission of the KU Alzheimer's Disease Center is to improve the lives of patients and families with Alzheimer's disease by eliminating the disease through research into its treatment and prevention.

Join our team – Make an impact

Apply for a Clinical Trial!

Last modified: Sep 21, 2018
How to Join

ApplyForStudyButton



Questions?

Email KUAMP@kumc.edu

or call (913) 588-0555.

ID=x10454